Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New scan could spot hidden cancers

NCT ID NCT03164486

Diagnosis Sponsor: Julie L. Sutcliffe, Ph.D Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new radioactive tracer called 18F-alphavbeta6-binding-peptide to see if it can safely and clearly show cancers in the breast, colon, lung, or pancreas. About 27 adults with these cancers will get the tracer and have a PET scan. The goal is to find out if this method can help doctors locate tumors better than current scans.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Early phase 1

The earliest testing in people: a first look at safety, in a very small group.

Participants

About 27 people

The number the study aims to enrol. It can still change while the study runs.

Start date

Nov 2016

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosed with primary or metastatic cancer in one or more of the following locations: breast, colorectal, lung, pancreas * Eastern Cooperative Oncology Group (ECOG) performance score of 0-1 * Will sign the Institutional Review Board (IRB)-approved consent form * Able to remain motionless for up to 30-60 minutes per scan Exclusion Criteria: * Creatinine \> 2 x upper limit of normal * Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \> 2 x upper limit of normal * Life expectancy \< 3 months (mo) * Women who are pregnant or breast-feeding * Patients who cannot undergo PET/compute tomography (CT) scanning * Lack of availability for follow-up assessments * Participation in another clinical trial involving an investigational agent within 4 weeks of enrollment

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm colorectal carcinoma colorectal neoplasm exocrine pancreatic carcinoma lung carcinoma lung neoplasm metastatic malignant neoplasm metastatic malignant neoplasm in the colon pancreatic adenocarcinoma pancreatic neoplasm rectal cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast carcinoma Colorectal carcinoma Lung carcinoma Metastatic malignant neoplasm in the breast Metastatic malignant neoplasm in the colon Metastatic malignant neoplasm in the lung Metastatic malignant neoplasm in the rectum Pancreatic carcinoma

Contacts and locations

Locations

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California, 95817, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.